Toward a Standard Practice to Quantify von Willebrand Factor Degradation During Left Ventricular Assist Device Support

被引:10
|
作者
Hennessy-Strahs, Samson [1 ]
Bermudez, Christian A. [1 ]
Acker, Michael A. [1 ]
Bartoli, Carlo R. [1 ]
机构
[1] Hosp Univ Penn, Div Cardiovasc Surg, 3400 Spruce St, Philadelphia, PA 19104 USA
来源
ANNALS OF THORACIC SURGERY | 2021年 / 112卷 / 04期
关键词
LONG-TERM SUPPORT; FACTOR PROFILES; HIGH PREVALENCE; IMPLANTATION; CENTRIFUGAL; CONTRIBUTES;
D O I
10.1016/j.athoracsur.2020.09.039
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Continuous-flow left ventricular assist devices (LVADs) cause degradation of von Willebrand factor (VWF) multimers and bleeding. Multiple techniques exist to characterize VWF deficiency. However, a standard methodology has not been established in LVAD patients. Toward this goal, we evaluated 4 methods to quantify VWF multimers. Methods. We collected paired blood samples from patients (n = 48) before and after 1 week of LVAD support. After 652 +/- 59 days of support, patients were classified as bleeders (>= 1 bleeding episode) or nonbleeders. VWF mul- timers were resolved with electrophoresis and immuno-blotting, the gold-standard to evaluate VWF multimers. We evaluated 4 quantification methods. Results. Each method demonstrated significant VWF degradation during LVAD support vs a paired, pre-LVAD sample (method 1, VWF length: 48 of 48 patients, -10% +/- 1%, P < .0001; method 2, VWF density: 40 of 48, -34% (interquartile range, -46% to -8%), P < .0001; method 3, pre-LVAD to LVAD ratio: 46 of 48, 17 +/- 5: 10 +/- 1, P < .0001; method 4, LVAD/pre-LVAD index: 46 of 48, 57% (inter-quartile range, 50% to 73%), P < .0001). Bleeding occurred in 27 of 48 patients. Method 1 demonstrated significantly fewer VWF multimers in bleeders compared with non-bleeders (-11% +/- 1% vs -8% +/- 1%; P = .01). Other methods did not demonstrate this potentially important clinical relationship. Conclusions. A standardized methodology is needed to quantify VWF multimer degradation with mechanical circulatory support devices. Novel method 1 successfully quantified the patient-specific change in VWF multimer length during LVAD support and demonstrated a difference in VWF multimers between bleeders and non-bleeders. Adoption of consensus methodology will assist to standardize patient-specific bleeding risk, inform anticoagulation and antiplatelet therapy, and evaluate LVAD hemocompatibility. (C) 2021 by The Society of Thoracic Surgeons
引用
收藏
页码:1257 / 1264
页数:8
相关论文
共 50 条
  • [21] Pathologic von Willebrand factor degradation is a major contributor to left ventricular assist device-associated bleeding: pathophysiology and evolving clinical management
    Bartoli, Carlo R.
    ANNALS OF CARDIOTHORACIC SURGERY, 2021, 10 (03) : 389 - 392
  • [22] Acquired von Willebrand Syndrome in Patients With an Axial Flow Left Ventricular Assist Device
    Meyer, Anna L.
    Malehsa, Doris
    Bara, Christoph
    Budde, Ulrich
    Slaughter, Mark S.
    Haverich, Axel
    Strueber, Martin
    CIRCULATION-HEART FAILURE, 2010, 3 (06) : 675 - 681
  • [23] Aortic regurgitation during left ventricular assist device support
    Haghi, Dariusch
    Suselbeck, Tim
    Saur, Joachim
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2007, 26 (11): : 1220 - 1221
  • [24] Neurohormonal Blockade During Left Ventricular Assist Device Support
    Imamura, Teruhiko
    Mehta, Priya
    Nguyen, Ann
    Chung, Ben
    Narang, Nikhil
    Rodgers, Daniel
    Raikhelkar, Jayant
    Smith, Bryan
    Song, Tae
    Ota, Takeyoshi
    Jeevanandam, Valluvan
    Kim, Gene
    Sayer, Gabriel
    Uriel, Nir
    ASAIO JOURNAL, 2020, 66 (08) : 881 - 885
  • [25] Vancomycin Use During Left Ventricular Assist Device Support
    Eyler, Rachel F.
    Butler, Simona O.
    Walker, Paul C.
    DePestel, Daryl D.
    Spoor, Martinus T.
    Pagani, Francis D.
    Malani, Preeti N.
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2009, 30 (05): : 484 - 486
  • [26] Left ventricular function during support with an asynchronous pulsatile left ventricular assist device
    Dalby, MCD
    Banner, NR
    Tansley, P
    Grieve, LA
    Partridge, J
    Yacoub, MH
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2003, 22 (03): : 292 - 300
  • [27] Comparative analysis of von Willebrand factor profiles after implantation of left ventricular assist device and total artificial heart
    Reich, H. J.
    Morgan, J.
    Arabia, F.
    Czer, L.
    Moriguchi, J.
    Ramzy, D.
    Esmailian, F.
    Lam, L.
    Dunhill, J.
    Volod, O.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2017, 15 (08) : 1620 - 1624
  • [28] GI Bleeding and Left Ventricular Assist Device - Is Acquired von Willebrand Syndrome the Final Answer?
    Brown, Janine
    Johnson, David
    Smith, Brenda
    Alexander, Burton
    Herre, John
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S428 - S429
  • [29] Acquired von Willebrand disease in a child with a ventricular assist device
    Nubret, Karine
    Mauriat, Philippe
    Roubertie, Francois
    James, Chloe
    Tafer, Nadir
    Ouattara, Alexandre
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2013, 146 (04): : E30 - E32
  • [30] Acquired von Willebrand Syndrome in Patients With Ventricular Assist Device
    Rauch, Antoine
    Susen, Sophie
    Zieger, Barbara
    FRONTIERS IN MEDICINE, 2019, 6